World Health Organization sets NEW Guidelines for GLP-1 Drugs (Ozempic, Wegovy, Mounjaro, Zepbound)

The World Health Organization (WHO) has released new guidelines on GLP-1 inhibitors (Ozempic, Wegovy, Mounjaro, and Zepbound, etc.) outlining how these medications should be used in the global fight against rising obesity rates. Originally created for type 2 diabetes, GLP-1 medications help manage hunger and support weight loss. The WHO emphasizes early intervention, lifestyle changes, and behavioral support alongside medication for long-term success.The new guidelines also highlight major challenges, including drug availability, high costs, and the future of GLP-1 inhibitors as patents of active ingredients (i.e. semaglutide) start to expire. With obesity affecting over 1 billion people worldwide, these recommendations aim to expand access, reduce global obesity rates, and improve outcomes. This video breaks down what the WHO’s GLP-1 guidance means for weight loss, health, and your fitness journey.Coach Julio is an expert in fitness and nutrition, having helped hundreds of busy office professionals and parents in their 30s, 40s, and 50s be their healthiest with personalized training plans and nutritionist counseling services. He works out of El Paso, Texas, but also offers remote nutritionist counseling and online personal training. Coach Julio’s expertise is backed by over nine years as a personal trainer and a Master’s degree in Nutrition.For information about working with Coach Julio for online personal training and nutritionist services, visit https://www.365physique.comFollow Coach Julio on these socials:FacebookInstagramTikTokLinkedIn